IART

Integra LifeSciences Holdings Corporation

Integra Lifesciences Holdings Corp is engaged in development, manufacturing, and marketing of product lines from its technology for applications ranging from burn and deep tissue wounds to repair of dura mater in the brain to repair of nerve and tendon.

Integra LifeSciences Holdings Corporation (IART) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Growth (C-). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
C
Factor Score 2.4 / 5.0
Growth
C-
Factor Score 1.9 / 5.0
Profitability
B-
Factor Score 3.1 / 5.0
Momentum
C+
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 86.9
EV / EBITDA 8.9
Rev Growth YoY 2.3%
Gross Margin 55.5%
Price Return 3M -19.0%
Price Return 12M 21.3%
Catalyst Signal 0.00
Market Cap $1.1B
TTM Revenue $1.7B
Price / Sales 0.7
ROE 1.2%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C (2.4) C- (1.9) B- (3.1) C+ (2.5) C+ (2.6) C+ (2.5)
2026-11-05 C (2.4) C- (1.9) B- (3.1) C+ (2.6) C+ (2.7) C+ (2.5)
2026-10-29 C+ (2.5) C- (1.9) B- (3.1) B- (3.0) C+ (2.7) C+ (2.6)
2026-10-22 C+ (2.6) C- (1.9) B (3.2) C+ (2.6) C+ (2.6) C+ (2.6)
2026-10-15 B (3.3) C- (1.9) B (3.2) C+ (2.7) C+ (2.6) C+ (2.7)
Page 1 of 8
…